# Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases

> **NCT00949247** · EARLY_PHASE1 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 20 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **BIOLOGICAL:** trastuzumab
- **DRUG:** carboplatin
- **DRUG:** docetaxel
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00949247
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00949247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00949247, "Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00949247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*